2018 in review: Alzheimer’s falters while oncology shinesGoing into 2018 you might have expected this to be the year of Alzheimer’s drugs, with several promising Share X2018 in review: Alzheimer’s falters while oncology shineshttps://pharmaphorum.com/r-d/views-analysis-r-d/2018-review-alzheimers-research-oncology/
2018 in review: AI on the rise in digital pharmaDigital technology is playing an increasingly important role in healthcare, and in the pharma industry as it searches Share X2018 in review: AI on the rise in digital pharmahttps://pharmaphorum.com/views-analysis-digital/2018-digital-review-ai-on-the-rise-in-pharma/
2018 in review: Humira biosimilars arrive in EuropeThe emergence this year of Humira biosimilars in Europe followed a period of sustained momentum around the cheaper Share X2018 in review: Humira biosimilars arrive in Europehttps://pharmaphorum.com/views-analysis-sales-marketing/2018-review-humira-biosimilars-europe/
2018 in review: Merck & Co sets new standards in oncology, CAR-Ts hit EU marketOncology drugs are developing at a fast pace, but 2018 was the year when immune-oncology set new standards Share X2018 in review: Merck & Co sets new standards in oncology, CAR-Ts hit EU markethttps://pharmaphorum.com/views-analysis-oncology/2018-in-review-merck-co-sets-new-standards-in-oncology-car-ts-hit-eu-market/
2018 in review: Governments start taking access seriouslyMarket access has become a key focus for governments across the globe in 2018 – though as ever Share X2018 in review: Governments start taking access seriouslyhttps://pharmaphorum.com/views-analysis-market-access/2018-in-review-governments-start-taking-access-seriously/
2018 in review: How patient centricity led to new drugs that tackle unmet needThe trend for working with patients, advocacy groups and appraisal authorities has yielded potentially life-changing results for patient Share X2018 in review: How patient centricity led to new drugs that tackle unmet needhttps://pharmaphorum.com/views-analysis-patients/2018-in-review-how-patient-centricity-led-to-new-drugs-that-tackle-unmet-need/
